Is Amplia Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Amplia Therapeutics Ltd (ATX.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Amplia Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amplia Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Amplia Therapeutics Ltd?

Muslim investors may consider investing in Amplia Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Amplia Therapeutics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Amplia Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Amplia Therapeutics Ltd updated?

The Shariah compliance status of Amplia Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Amplia Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Amplia Therapeutics Ltd?

You can check the latest Shariah compliance status of Amplia Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ATX.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 30, 2025

Report Source: 2025 Annual Report

Analyst's Ratings for Amplia Therapeutics Ltd (ATX.AX)

Based on 5 analysts giving stock ratings to Amplia Therapeutics Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Amplia Therapeutics Ltd. Stock Analysis ATX.AX

Australia Health Care Micro Cap Report: 2025 Annual

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.

Key Statistics of Amplia Therapeutics Ltd (ATX.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.15AUD0.17

Today's Open

AUD0.17

Volume

242.64K

P/E Ratio (TTM)

52 Week Range

AUD0.05AUD0.43

Market Cap

76.96M

Avg. Volume

1.35M

Dividend Yield

Financial Metrics & Statements of Amplia Therapeutics Ltd (ATX.AX)

FAQ's for Amplia Therapeutics Ltd (ATX.AX)

According to Musaffa’s Shariah screening methodology, Amplia Therapeutics Ltd (ATX.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.